Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~IFG, or IGT BMI 27.0-37.0 kg/m2~Exclusion Criteria:~DM, CAD, severe anemia, kidney or liver disease, hx of pancreatitis, gallstones, ETOH abuse, personnel or family history of medullary thyroid carcinoma or MEN-2

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
- liraglutide (Type: ACTIVE_COMPARATOR): Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).